Alumis (ALMS) Current Deferred Revenue (2025)
Alumis (ALMS) reported Current Deferred Revenue of $1.5 million for Q4 2025.
Alumis (ALMS) Current Deferred Revenue (2025) Analysis & Trends
Alumis (ALMS) has 1 years of Current Deferred Revenue data on file, last reported at $1.5 million in Q4 2025.
- Current Deferred Revenue for Q4 2025 came in at $1.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $1.5 million (changed N/A YoY), and the FY2025 annual result was $1.5 million, changed N/A from the prior year.
- Current Deferred Revenue was little changed at $1.5 million in Q4 2025 per ALMS's latest filing.
- Over five years, Current Deferred Revenue peaked at $1.5 million in Q4 2025 and troughed at $1.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Alumis | 1.99 Bn | 1.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.46 Mn |